Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 32
Filter
1.
Neuromuscul Disord ; 24(11): 986-9, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25047667

ABSTRACT

Duchenne muscular dystrophy (DMD), a severe and lethal condition, is caused by the absence of muscle dystrophin. Therapeutic trials aiming at the amelioration of muscle function have been targeting the production of muscle dystrophin in affected Duchenne patients. However, how much dystrophin is required to rescue the DMD phenotype remains an open question. We have previously identified two exceptional golden retriever muscular dystrophy (GRMD) dogs with a milder course despite the total absence of muscle dystrophin. Here we report two unusual patients carrying nonsense mutations in the DMD gene and dystrophin deficiency but with an unexpectedly mild phenotype. Three reported polymorphisms, respectively in genes LTBP4, SPP1 and ACTN3 were excluded as possible DMD genetic modifiers in our patients. Finding the mechanisms that protect some rare patients and dogs from the deleterious effect of absent muscle dystrophin is of utmost importance and may lead to new avenues for treatment. Importantly, these observations indicate that it is possible to have a functional large muscle even without dystrophin.


Subject(s)
Codon, Nonsense/genetics , Dystrophin/genetics , Muscular Dystrophy, Duchenne/genetics , Actins/genetics , Adolescent , Female , Humans , Latent TGF-beta Binding Proteins/genetics , Male
2.
Neuromuscul Disord ; 14(5): 313-20, 2004 May.
Article in English | MEDLINE | ID: mdl-15099590

ABSTRACT

The most frequent inherited peripheral neuropathy is the peripheral myelin protein 22 (PMP22) gene related disease. Duplication, deletion, and point mutations in that gene are associated with phenotypic variability. Here we report a family carrying a novel mutation in the PMP22 gene (c. 327C>A), which results in a premature stop codon (Cys109stop). The family members who carry this mutation have a Charcot-Marie-Tooth type 1 variable phenotype, ranging from asymptomatic to severely affected. These findings suggest that the fourth transmembrane domain of the PMP22 gene may play an important role, although the intrafamilial clinical variability reinforces the observation that pathogenic mutations are not always phenotype determinant and that other factors (genetic or epigenetic) modulate the severity of the clinical course.


Subject(s)
Charcot-Marie-Tooth Disease/genetics , Codon, Terminator/genetics , Mutation , Myelin Proteins/genetics , Phenotype , Adolescent , Adult , Aged , Axons/pathology , Axons/ultrastructure , Biopsy/methods , Charcot-Marie-Tooth Disease/physiopathology , Cysteine/genetics , DNA Mutational Analysis/methods , Family Health , Female , Humans , Male , Microscopy, Electron/methods , Middle Aged , Neurologic Examination/methods , Pedigree , Polymerase Chain Reaction , Polymorphism, Single-Stranded Conformational , Sural Nerve/pathology , Sural Nerve/ultrastructure
5.
Genet Epidemiol ; 23(4): 364-74, 2002 Nov.
Article in English | MEDLINE | ID: mdl-12432504

ABSTRACT

The BCL3 gene has been considered a susceptibility locus for nonsyndromic cleft lip with or without cleft palate (NSCL/P), based on association and linkage studies in some populations. We evaluated an intragenic marker at the BCL3 gene and the microsatellite D19S178 (1.1 cM distant from the BCL3 gene) among 98 infants born with NSCL/P and their parents, using the transmission disequilibrium test (TDT) and a method for haplotype analysis. Our analysis, based on BCL3 alleles, revealed the existence of a marginal association of allele 135pb of the BCL3 gene with NSCL/P (chi(2)=3.60; P=0.058; 1 df), with a major effect in female (chi(2)=5.77; P=0.016; 1 df) and in familial cases (chi(2)=3.79; P=0.051; 1 df). However, the haplotype analysis detected no significant segregation distortion, even if the alleles of the D19S178 were grouped into two classes. These findings support previous findings that BCL3 plays a role in the etiology of NSCL/P as an allele of low penetrance or as a modifier locus. We hypothesize that there might be more than one mutation in this gene associated with NSCL/P, or alternatively, that more than one mutation has arisen associated with the 135-bp allele. Genet. Epidemiol. 23:364-374, 2002


Subject(s)
Cleft Lip/genetics , Cleft Palate/genetics , Genetic Linkage , Proto-Oncogene Proteins/genetics , Alleles , B-Cell Lymphoma 3 Protein , Brazil/epidemiology , Chi-Square Distribution , Cleft Lip/epidemiology , Cleft Palate/epidemiology , DNA/analysis , Female , Genotype , Haplotypes , Humans , Infant, Newborn , Lod Score , Male , Phenotype , Polymerase Chain Reaction , Transcription Factors
6.
J Mol Neurosci ; 17(1): 71-80, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11665864

ABSTRACT

Dysferlin is the protein product of the DYSF gene mapped at 2p31, which mutations cause limb-girdle muscular dystrophy type 2B (LGMD2B) and Miyoshi myopathy. To date, nine autosomal recessive forms (AR-LGMD) have been identified: four genes, which code for the sarcoglycan glycoproteins, are associated with both mild and severe forms, the sarcoglycanopathies (LGMD2C, 2D, 2E and 2F). The other five forms, usually causing a milder phenotype are LGMD2A (calpain 3), LGMD2B (dysferlin), LGMD2G (telethonin), LGMD2H (9q31-11), and LGMD21 (19q13.3). We studied dysferlin expression in a total of 176 patients, from 166 LGMD families: 12 LGMD2B patients, 70 with other known forms of muscular dystrophies (LGMD2A, sarcoglycanopathies, LGMD2G), in an attempt to assess the effect of the primary gene-product deficiency on dysferlin. In addition, 94 still unclassified LGMD families were screened for dysferlin deficiency. In eight LGMD2B patients from five families, no dysferlin was observed in muscle biopsies, both through immunofluorescence (IF) and Western blot methodologies, while in two families, a very faint band was detected. Both patterns, negative or very faint bands, were concordant in patients belonging to the same families, suggesting that dysferlin deficiency is specific to LGMD2B. Myoferlin, the newly identified homologue of dysferlin was studied for the first time in LGMD2B patients. Since no difference was observed between patients mildly and severely affected, this protein do not seem to modify the phenotype in the present dysferlin-deficient patients. Dystrophin, sarcoglycans, and telethonin were normal in all LGMD2B patients, while patients with sarcoglycanopathies (2C, 2D, and 2E), LGMD2A, LGMD2G, and DMD showed the presence of a normal dysferlin band by Western blot and a positive pattern on IF. These data suggest that there is no interaction between dysferlin and these proteins. However, calpain analysis showed a weaker band in four patients from two families with intra-familial concordance. Therefore, this secondary deficiency of calpain in LGMD2B families, may indicate an interaction between dysferlin and calpain in muscle. Dysferlin was also present in cultured myotubes, in chorionic villus, and in the skin. Dysferlin deficiency was found in 24 out of a total of 166 Brazilian AR-LGMD families screened for muscle proteins (approximately 14%), thus representing the second most frequent known LGMD form, after calpainopathy, in our population.


Subject(s)
Membrane Proteins , Muscle Proteins/metabolism , Muscle, Skeletal/physiopathology , Muscular Dystrophies/metabolism , Adult , Age of Onset , Calcium-Binding Proteins , Calpain/genetics , Calpain/metabolism , Child , Connectin , Dysferlin , Dystrophin/genetics , Dystrophin/metabolism , Female , Genetic Linkage , Humans , Immunohistochemistry , Male , Middle Aged , Muscle Proteins/genetics , Muscle, Skeletal/pathology , Muscular Dystrophies/diagnosis , Muscular Dystrophies/genetics , Mutation , Polysaccharides/genetics , Polysaccharides/metabolism
7.
Muscle Nerve ; 23(6): 984-8, 2000 Jun.
Article in English | MEDLINE | ID: mdl-10842281

ABSTRACT

In patients with sarcoglycan (SG) deficiency, a primary defect in any one of the four SG proteins usually leads to reduced expression of the whole SG complex. We report a limb-girdle muscular dystrophy type 2D family (LGMD2D), with variable phenotype, where a mutation in the alpha-SG gene resulted in the partial deficiency of alpha-SG alone. The normal expression of the other three SG proteins suggests that mutations close to the alpha-SG transmembrane domain might be less critical for complex integrity, and that weakness may occur despite its retention.


Subject(s)
Cytoskeletal Proteins/genetics , Dystrophin/genetics , Family Health , Glycoproteins/genetics , Membrane Glycoproteins/genetics , Muscular Dystrophies/genetics , Adult , Biopsy , Dystrophin/analysis , Glycoproteins/analysis , Humans , Male , Muscle, Skeletal/chemistry , Muscle, Skeletal/pathology , Muscular Dystrophies/pathology , Mutation , Nuclear Family , Pedigree , Polymorphism, Single-Stranded Conformational , Sarcoglycans
8.
Am J Med Genet ; 86(5): 447-53, 1999 Oct 29.
Article in English | MEDLINE | ID: mdl-10508987

ABSTRACT

The aim of the present study was to assess the impact of genetic counseling in young women at risk to have Duchenne muscular dystrophy (DMD) children prior to childbearing. A total of 263 potential DMD carriers, who had had genetic counseling and were given different genetic risks, were included in this investigation. Their reproductive outcome and future plans as well as their requests for DNA tests (for carrier detection and prenatal diagnosis) were analyzed according to genetic risk magnitude, comprehension of genetic counseling is- sues, family and personal history, socio-educational level, and subjective opinion about selective abortion. We noted that genetic risk magnitude had no significant influence on reproductive plans or outcome nor on the request for additional DNA testing, even considering only those clients with good comprehension and retention of issues discussed during genetic counseling. On the other hand, counselees who had more than one affected or at least one deceased DMD case in their family understood genetic counseling significantly better, suggesting that "learning with life" has a stronger impact than genetic counseling.


Subject(s)
Family Planning Services , Genetic Counseling , Muscular Dystrophy, Duchenne/epidemiology , Muscular Dystrophy, Duchenne/genetics , Parity , Adult , Attitude to Health , DNA/genetics , Female , Follow-Up Studies , Genetic Carrier Screening , Humans , Prenatal Diagnosis , Risk Factors
10.
Am J Hum Genet ; 65(2): 433-40, 1999 Aug.
Article in English | MEDLINE | ID: mdl-10417286

ABSTRACT

van der Woude syndrome (VWS), which has been mapped to 1q32-41, is characterized by pits and/or sinuses of the lower lip, cleft lip/palate (CL/P), cleft palate (CP), bifid uvula, and hypodontia (H). The expression of VWS, which has incomplete penetrance, is highly variable. Both the occurrence of CL/P and CP within the same genealogy and a recurrence risk <40% for CP among descendants with VWS have suggested that the development of clefts in this syndrome is influenced by modifying genes at other loci. To test this hypothesis, we have conducted linkage analysis in a large Brazilian kindred with VWS, considering as affected the individuals with CP, regardless of whether it is associated with other clinical signs of VWS. Our results suggest that a gene at 17p11.2-11.1, together with the VWS gene at 1p32-41, enhances the probability of CP in an individual carrying the two at-risk genes. If this hypothesis is confirmed in other VWS pedigrees, it will represent one of the first examples of a gene, mapped through linkage analysis, which modifies the expression of a major gene. It will also have important implications for genetic counseling, particularly for more accurately predicting recurrence risks of clefts among the offspring of patients with VWS.


Subject(s)
Chromosomes, Human, Pair 17/genetics , Cleft Palate/genetics , Genetic Linkage/genetics , Genetic Predisposition to Disease/genetics , Abnormalities, Multiple , Brazil , Chromosomes, Human, Pair 1/genetics , Family Health , Female , Genetic Markers/genetics , Genotype , Haplotypes , Humans , Lod Score , Male , Molecular Sequence Data , Pedigree , Penetrance , Phenotype , Syndrome
11.
J Neurol Sci ; 164(1): 44-9, 1999 Mar 15.
Article in English | MEDLINE | ID: mdl-10385046

ABSTRACT

Sarcoglycanopathies (SGPs) constitute a subgroup of limb-girdle muscular dystrophies (LGMD), where the primary defect in one sarcoglycan (SG) glycoprotein (alpha-SG, beta-SG, gamma-SG or delta-SG) results in a deficiency of the whole complex. Four genes, at 17q, 4q, 13q and 5q, encode the four glycoproteins, and mutations in these genes cause diseases called LGMD2D, 2E, 2C and 2F. To estimate the prevalence, relative proportions and clinical features of SGPs, we have studied the SG proteins in muscle biopsies of 140 patients (from 115 unrelated Brazilian families) with a clinical diagnosis of LGMD. Alpha-SG immunofluorescence analysis showed a positive staining pattern in 70% (80/115) of the families, a patchy pattern in 14% (16/115) and a negative pattern in 16% (19/115) of the families. All the 19 alpha-SG negative, and four of the 16 alpha-SG patchy patients were also deficient for the other three SG proteins, confirming the diagnosis of SGP in 20% of the LGMD families. None of the positive alpha-SG patients were deficient for any of the other three SG proteins, supporting the view that the SG complex functions as a unit. DNA analysis for the four sarcoglycan genes showed that alpha-SG mutations accounted for 47%, beta-SG for 16%, gamma-SG for 16% and delta-SG for 21% of the cases. SG abnormalities were observed in only 8.5% of patients with milder LGMD forms, but were present in 68% of patients with a severe Duchenne-like course. The relatively high frequency of SGP among Brazilian people with LGMD may be due to the disproportionally high frequency of African Brazilian SGP patients with the same mutation (particularly among LGMD2C and 2F patients), suggesting a founder effect. Consanguinity is also common in our SGP families.


Subject(s)
Cytoskeletal Proteins/genetics , Muscular Dystrophies/genetics , Adolescent , Adult , Brazil/epidemiology , Child , Cytoskeletal Proteins/analysis , DNA Mutational Analysis , Dystroglycans , Female , Humans , Male , Membrane Glycoproteins/analysis , Membrane Glycoproteins/genetics , Muscle, Skeletal/chemistry , Muscular Dystrophies/diagnosis , Muscular Dystrophies/epidemiology , Sarcoglycans
12.
Am J Med Genet ; 77(2): 155-61, 1998 May 01.
Article in English | MEDLINE | ID: mdl-9605290

ABSTRACT

We investigated 52 families of patients with facioscapulohumeral muscular dystrophy (FSHD1), including 172 patients (104 males and 68 females). Among 273 DNA samples which were analyzed with probe p13E-11, 131 (67 males and 64 females) were shown to carry an EcoRI fragment smaller than 35 kb; 114 among them were examined clinically and neurologically. Results of the present investigation showed that: a) there is no molecular evidence for autosomal or X-linked recessive inheritance of FSHD1; b) an excess of affected males, which is explained by a significantly greater proportion of females than males among asymptomatic cases and a significantly greater proportion of affected sons than daughters observed in the offspring of asymptomatic mothers; c) the penetrance of the FSHD1 gene until age 30 was estimated as 83% for both sexes but was significantly greater for males (95%) than for females (69%); d) new mutations occur significantly more frequently in females than males among somatic/germinal mosaic cases; and e) severely affected cases originated more often through new mutations or were transmitted through maternal than through paternal lines including somatic/germinal mothers. These observations have important implications for understanding the molecular mechanisms responsible for FSHD1 and for genetic and prognostic counseling according to the gender of the affected patient.


Subject(s)
Muscular Dystrophies/genetics , Penetrance , Proteins/genetics , Adolescent , Adult , Child , Deoxyribonuclease EcoRI , Female , Genes, Dominant , Genes, Recessive , Heterozygote , Humans , Male , Microfilament Proteins , Middle Aged , Mosaicism/genetics , Mutation , Nuclear Proteins , Pedigree , Phenotype , Polymorphism, Restriction Fragment Length , RNA-Binding Proteins , Sequence Deletion , Sex Factors
13.
Hum Mutat ; 10(3): 217-22, 1997.
Article in English | MEDLINE | ID: mdl-9298822

ABSTRACT

Duchenne (DMD) and Becker (BMD) type muscular dystrophies are allelic X-linked recessive disorders caused by mutations in the gene encoding dystrophin. About 65% of the cases are caused by deletions, while 5-10% are duplications. The remaining 30% of affected individuals may have smaller mutations (point mutations or small deletions/insertions) which cannot be identified by current diagnostic screening strategies. In order to look for pathogenic small mutations in the dystrophin gene, we have screened the 18 exons located in the hot spot region of this gene through two different single strand conformation polymorphism (SSCP) conditions. Five different pathogenic mutations were identified in 6 out of 192 DMD/BMD patients without detectable deletions: 2 nonsense, 1 bp insertion, 1 bp deletion and 1 intronic. Except for the intronic change, which alters a splice site, all the others cause a premature stop codon. In addition, 8 apparently neutral changes were identified. However, interestingly, one of them was not identified in 195 normal chromosomes, although it was previously described in a DMD patient from a different population. The possibility that this mutation may be pathogenic is discussed. Except for two neutral changes, all the others are apparently here described for the first time.


Subject(s)
Dystrophin/genetics , Point Mutation , Dystrophin/chemistry , Gene Deletion , Genetic Testing , Humans , Male , Muscular Dystrophies/etiology , Muscular Dystrophies/genetics , Polymorphism, Genetic , Polymorphism, Single-Stranded Conformational
14.
Hum Mol Genet ; 5(12): 1953-61, 1996 Dec.
Article in English | MEDLINE | ID: mdl-8968749

ABSTRACT

Autosomal recessive limb-girdle muscular dystrophies (LGMDs) are genetically heterogeneous. A subgroup of these disorders is caused by mutations in the dystrophin-associated sarcoglycan complex. Truncating mutations in the 43 kDa beta-sarcoglycan gene (LGMD 2E) were originally identified in a sporadic case of Duchenne-like muscular dystrophy, and a common missense mutation (T151R) was identified independently in Indiana Amish pedigrees with a milder form of LGMD. To facilitate mutational analysis of larger numbers of patients directly from genomic DNA, as opposed to reverse transcribed RNA from muscle biopsies, we have determined the genomic structure of the beta-sarcoglycan gene. The open reading frame of the beta-sarcoglycan coding region extends over six exons. Primers were designed for PCR amplification of single exons from genomic DNA and subsequent single strand conformation polymorphism (SSCP) analysis. We screened 15 patients from the Brazilian LGMD patient population, 13 of whom followed a severe course. Most of the patients had been assessed previously for deficiency of alpha-sarcoglycan immunofluorescence on muscle biopsy sections as a marker for disease of the sarcoglycan complex. Novel mutations in two familial and two sporadic cases of severe childhood-onset LGMD were identified. Only one of these patients carried a truncating mutation (homozygous 2 bp deletion, FS164TER), while the other three carried missense mutations (homozygous R91P, homozygous M100K, heterozygous recessive L108R; only one allele could be identified in this family). All three missense mutations occurred in exon 3, coding for the immediate extracellular domain. Complete absence for all three of the known sarcoglycans was noted by immunohistochemistry on muscle biopsy sections of the patients.


Subject(s)
Cytoskeletal Proteins/genetics , Genome, Human , Membrane Glycoproteins/genetics , Muscular Dystrophies/genetics , Amino Acid Sequence , Base Sequence , Dystroglycans , Exons/genetics , Female , Humans , Male , Molecular Sequence Data , Mutation , Polymorphism, Genetic
15.
Hum Mol Genet ; 5(12): 1963-9, 1996 Dec.
Article in English | MEDLINE | ID: mdl-8968750

ABSTRACT

To enhance our understanding of the autosomal recessive limb-girdle muscular dystrophy (LGMD), patients from six genetically distinct forms (LGMD2A to LGMD2F) were studied with antibodies directed against four sarcoglycan subunits (alpha-, beta-, gamma-, delta-SG), dystrophin, beta-dystroglycan (beta-DG) and merosin. All patients with LGMD2A and 2B had a mild clinical course while those with a primary sarcoglycan mutation (LGMD2C to 2F) had a range of clinical severity. Dystrophin and merosin immunofluorescence pattern was positive in patients with all six AR LGMDs. The majority of patients with a severe Duchenne-like phenotype presented total absence of the SG complex. However, some exceptions were found in 13q linked patients, indicating that the presence of a certain labelling for components of the SG may not be prognostic for a milder phenotype. The observation that the primary absence of alpha-SG results in the total absence of beta- and delta-SG but not of gamma-SG suggests that the alpha-, beta- and delta-subunits of sarcoglycan may be more closely associated. A secondary reduction in dystrophin amount was seen in patients with primary sarcoglycan mutations, which was most marked in patients with primary beta-, gamma- and delta-SG deficiencies. In contrast, beta-DG staining was retained in all patients, suggesting that the association between SG and DG subcomplexes is not so strong. Based on the above findings, we have refined the model for the interaction among the known glycoproteins of the sarcoglycan complex, within the DGC.


Subject(s)
Cytoskeletal Proteins/analysis , Dystrophin/analysis , Laminin/analysis , Membrane Glycoproteins/analysis , Muscular Dystrophies/metabolism , Adolescent , Adult , Child , Dystroglycans , Female , Humans , Immunohistochemistry , Male , Muscular Dystrophies/genetics , Mutation
16.
Neuropediatrics ; 26(6): 293-7, 1995 Dec.
Article in English | MEDLINE | ID: mdl-8719743

ABSTRACT

Recently, a deficiency of merosin has been reported in patients with classical congenital muscular dystrophy (CMD), while other patients, with indistinguishable clinico-pathological features, do not present this deficiency, suggesting genetic heterogeneity. The purpose of the present investigation was to assess merosin distribution and quantity in 21 clinically well characterized Brazilian CMD patients, in order to: a) estimate the proportion of merosin-deficient cases in this group of patients; b) characterize phenotypically merosin-negative, as compared to merosin-positive patients. Merosin deficiency was found in 11 patients and all the seven who had been submitted to neuroimaging studies showed evidence of periventricular dysmyelination. A normal pattern of 43 DAG was found in all patients, which suggest that this protein is not preferentially involved in a third form of merosin-positive CMD. Results from the present study are further suggestive, but do not prove, that the association of merosin deficiency with white matter alterations represents a genetic entity with common clinical, laboratory and neuroimaging findings.


Subject(s)
Brain/physiopathology , Demyelinating Diseases/physiopathology , Muscular Dystrophies/congenital , Muscular Dystrophies/physiopathology , Adolescent , Antibodies, Monoclonal , Blotting, Western , Child , Child, Preschool , Dystrophin/analysis , Humans , Immunohistochemistry , Infant , Magnetic Resonance Imaging , Muscles/chemistry , Muscular Dystrophies/diagnosis
17.
J Neurol Sci ; 131(1): 99-104, 1995 Jul.
Article in English | MEDLINE | ID: mdl-7561956

ABSTRACT

The differential diagnosis between autosomal recessive limb-girdle (LGMD) and X-linked Becker muscular dystrophy (BMD) is very important for genetic counseling. It has been hypothesized that all BMD patients would have dystrophin alterations and dystrophin analysis could identify the Xp21 MD. Qualitatively abnormal dystrophin is easily detectable, but it is generally associated with in-frame DNA deletions or duplications. In patients with no detectable DNA deletions, in which X-linked inheritance cannot be proved, dystrophin quantification is still the only available test for differential diagnosis. In order to assess the accuracy of dystrophin quantification test in delineating Becker patients, we analyzed dystrophin abundance in BMD patients with a positive history of X-linked inheritance and no DNA detectable mutation, as compared to patients from families with LGMD. We observed that patients from 2 among the 5 BMD families have nearly normal dystrophin, while alteration in dystrophin content was observed in patients from 2 among the 7 LGMD families studied (probably as a secondary effect of alteration in the whole dystrophin-glycoproteins complex). These results suggest that dystrophin quantification, as an isolated test is not helpful for differential diagnosis between BMD and LGMD.


Subject(s)
Dystrophin/metabolism , Muscular Dystrophies/metabolism , Adolescent , Adult , Blotting, Western , Child , Child, Preschool , Diagnosis, Differential , Dystrophin/analysis , Dystrophin/genetics , Female , Genetic Linkage , Humans , Male , Muscular Dystrophies/diagnosis , Muscular Dystrophies/genetics , Pedigree , X Chromosome
18.
Hum Mol Genet ; 4(3): 401-6, 1995 Mar.
Article in English | MEDLINE | ID: mdl-7795594

ABSTRACT

The purpose of this investigation was to analyze the CTG expansion in muscle as compared to lymphocytes DNA in a sample of selected myotonic dystrophy (DM) patients of different ages and degrees of clinical severity, ranging from severe congenital to minimally affected. Results from the present study showed that the size of the CTG repeat was markedly larger in skeletal muscle than in lymphocytes in all DM patients. In contrast to lymphocytes, no significant correlation was found between the size of the CTG expansion in muscle and age at onset. In addition, large expansions were observed in muscle from all adult symptomatic patients independently of the presence of muscle weakness, which raises the question of the value of analyzing CTG expansions in muscle for predicting the severity of the phenotype. Differences between the size of the CTG expansions in muscle as compared to lymphocytes were smaller in affected children suggesting an apparent tendency to increase with aging and reaching a plateau in adulthood.


Subject(s)
DNA/analysis , Muscle, Skeletal/chemistry , Myotonic Dystrophy/genetics , Protein Kinases/genetics , Protein Serine-Threonine Kinases , Repetitive Sequences, Nucleic Acid , Adolescent , Adult , Aged , Blotting, Southern , Child , Child, Preschool , Female , Genetic Heterogeneity , Humans , Lymphocytes/chemistry , Male , Middle Aged , Myotonic Dystrophy/physiopathology , Myotonin-Protein Kinase , Polymorphism, Restriction Fragment Length
19.
J Neurol Sci ; 123(1-2): 122-8, 1994 May.
Article in English | MEDLINE | ID: mdl-8064304

ABSTRACT

Recently, we have demonstrated the specific deficiency of the 50-kDa dystrophin-associated glycoprotein (50DAG) in severe childhood autosomal recessive muscular dystrophy with Duchenne-like phenotype (SCARMD or AR-DLMD), a disease first reported in Tunisia and now presumed to be prevalent in North Africa and the Middle East. Here we demonstrate the deficiency of the 50DAG in one caucasoid and 5 negroid Brazilian patients with severe muscular dystrophy, which confirms that AR-DLMD with the 50DAG deficiency is not confined to the Arab populations. Without the analysis of both dystrophin and 50DAG, isolated male patients with this condition could be undiagnosed or misdiagnosed as having Duchenne or severe Becker muscular dystrophy. We also report, for the first time, the normal expression of the 50DAG and other dystrophin-associated proteins in one negroid and 2 caucasoid Brazilian patients with a phenotype indistinguishable from that of AR-DLMD with 50DAG deficiency. This is consistent with the genetic heterogeneity for the phenotype of AR-DLMD.


Subject(s)
Cytoskeletal Proteins/analysis , Cytoskeletal Proteins/deficiency , Membrane Glycoproteins/analysis , Membrane Glycoproteins/deficiency , Muscles/pathology , Muscular Dystrophies/pathology , Adolescent , Age of Onset , Biopsy , Brazil , Child , Female , Genes, Recessive , Humans , Immunohistochemistry , Male , Muscular Dystrophies/genetics , Muscular Dystrophies/metabolism , Phenotype , Sarcoglycans
20.
Hum Mol Genet ; 2(5): 557-62, 1993 May.
Article in English | MEDLINE | ID: mdl-8518794

ABSTRACT

The gene responsible for facioscapulohumeral muscular dystrophy (FSHD), an autosomal dominant neuromuscular condition, has been mapped to chromosome 4. Until recently, the two closest available markers were D4S139 and D4S163 but a new marker (p13E-11) which recognizes de novo rearrangements in isolated cases of FSHD characterized by shorter EcoRI fragments has been now identified. Linkage analysis in FSHD families with p13E-11 shows that usually a smaller fragment segregates with the disease gene among the affected individuals from each genealogy. In the present paper, we report the results from linkage analysis with the marker loci D4S163 and D4S139 in 6 FSHD families and with p13E-11 in these and in 6 other additional Brazilian families (total of 12). The results from such analysis do not suggest genetic heterogeneity for FSHD in our population. In 11 out of the 12 families studied with p13E-11, a shorter specific EcoRI band was found to segregate in all affected patients from each genealogy. In one family, the normal individuals had a smaller EcoRI fragment than the affected ones. The size of the EcoRI fragments detected with p13E-11 varied from 13.5 to 29 kb but was constant within each genealogy. Our results suggest that the use of the marker p13E-11 for preclinical and prenatal diagnosis should be done only in families in which it is possible to identify the fragments segregating among the affected individuals.


Subject(s)
Chromosomes, Human, Pair 4 , Muscular Dystrophies/genetics , Adolescent , Adult , Aged , Aged, 80 and over , Brazil , Child , Child, Preschool , DNA Probes , Female , Genes, Dominant , Genetic Linkage , Genetic Markers , Humans , Lod Score , Male , Middle Aged , Muscular Dystrophies/diagnosis , Mutation , Pedigree
SELECTION OF CITATIONS
SEARCH DETAIL
...